Concert Pharmaceuticals, Inc operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, a once-nightly oxybate product; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone781-860-0045
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$10.51 million
Profitability
Miscellaneous
Employees71
Next Earnings Date11/7/2019 (Estimated)
OptionableOptionable
Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions
What is Concert Pharmaceuticals' stock symbol?
Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."
How were Concert Pharmaceuticals' earnings last quarter?
Concert Pharmaceuticals Inc (NASDAQ:CNCE) issued its quarterly earnings data on Thursday, August, 1st. The biotechnology company reported ($0.78) EPS for the quarter, beating the Zacks' consensus estimate of ($0.92) by $0.14. The biotechnology company had revenue of $0.05 million for the quarter, compared to analyst estimates of $0.30 million. Concert Pharmaceuticals had a negative return on equity of 49.44% and a negative net margin of 7,303.34%. View Concert Pharmaceuticals' Earnings History.
When is Concert Pharmaceuticals' next earnings date?
What price target have analysts set for CNCE?
7 equities research analysts have issued twelve-month target prices for Concert Pharmaceuticals' stock. Their predictions range from $8.00 to $25.00. On average, they expect Concert Pharmaceuticals' stock price to reach $16.29 in the next year. This suggests a possible upside of 177.0% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.
What is the consensus analysts' recommendation for Concert Pharmaceuticals?
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.
What are Wall Street analysts saying about Concert Pharmaceuticals stock?
Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (10/1/2019)
- 2. HC Wainwright analysts commented, "Our price target of $29/share is comprised of $10.39 from CTP-543 in AA + $3.81 from AVP-786 in AD + $8.60 in schizophrenia + $5.75 in cash and is based on a discounted cash flow analysis (2019-2026) using a 12% discount rate and 1% growth rate, in line with the expected discount and growth parameters of a development stage biotechnology company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition, and pricing." (8/2/2019)
- 3. Mizuho analysts commented, "We do not see earnings as the most meaningful indicator of value for developmental stage biotechs. Catalysts to watch: 1) CTP-543 Phase II data for alopecia areata (AA) is expected in 3Q19, 2) AVP-786 second Phase III trial is expected to complete in Dec 2019, data could be available in early 2020. Concert had $153.8mn at the end of 1Q19 which is expected to support operation through 2H20." (5/3/2019)
Has Concert Pharmaceuticals been receiving favorable news coverage?
News stories about CNCE stock have trended negative recently, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Concert Pharmaceuticals earned a news impact score of -2.6 on InfoTrie's scale. They also assigned media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days. View News Stories for Concert Pharmaceuticals.
Are investors shorting Concert Pharmaceuticals?
Concert Pharmaceuticals saw a decline in short interest in the month of September. As of September 30th, there was short interest totalling 927,900 shares, a decline of 9.0% from the August 30th total of 1,020,000 shares. Based on an average daily trading volume, of 208,700 shares, the days-to-cover ratio is presently 4.4 days. Currently, 4.4% of the company's stock are sold short. View Concert Pharmaceuticals' Current Options Chain.
Who are some of Concert Pharmaceuticals' key competitors?
Some companies that are related to Concert Pharmaceuticals include MacroGenics (MGNX), Revance Therapeutics (RVNC), Akero Therapeutics (AKRO), Flexion Therapeutics (FLXN), IGM Biosciences (IGMS), Basilea Pharmaceutica (BPMUF), Achillion Pharmaceuticals (ACHN), Akebia Therapeutics (AKBA), TG Therapeutics (TGTX), Aptorum Group (APM), Akorn (AKRX), Retrophin (RTRX), Catalyst Pharmaceuticals (CPRX), Viking Therapeutics (VKTX) and Sinovac Biotech (SVA).
What other stocks do shareholders of Concert Pharmaceuticals own?
Who are Concert Pharmaceuticals' key executives?
Concert Pharmaceuticals' management team includes the folowing people:
- Mr. Richard H. Aldrich Mba, Co-Founder & Chairman (Age 65)
- Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 59)
- Ms. Nancy Stuart, Chief Operating Officer (Age 61)
- Dr. James V. Cassella, Chief Devel. Officer (Age 64)
- Mr. Marc A. Becker, Chief Financial Officer (Age 47)
How do I buy shares of Concert Pharmaceuticals?
Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Concert Pharmaceuticals' stock price today?
One share of CNCE stock can currently be purchased for approximately $5.88.
How big of a company is Concert Pharmaceuticals?
Concert Pharmaceuticals has a market capitalization of $139.94 million and generates $10.51 million in revenue each year. The biotechnology company earns $-56,020,000.00 in net income (profit) each year or ($2.40) on an earnings per share basis. Concert Pharmaceuticals employs 71 workers across the globe.View Additional Information About Concert Pharmaceuticals.
What is Concert Pharmaceuticals' official website?
How can I contact Concert Pharmaceuticals?
Concert Pharmaceuticals' mailing address is 65 HAYDEN AVENUE SUITE 3000N, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]
MarketBeat Community Rating for Concert Pharmaceuticals (NASDAQ CNCE)
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
